ECM/Integrin signaling promotes resistance to the combination of HER2 and PI3K inhibitors in HER2+, PIK3CA-mutant breast cancer

被引：0
|
作者：
Hanker, Ariella B.
Estrada, Monica Valeria
Zhao, Junfei
Cheng, Feixiong
Moore, Preston D.
Tyson, Darren
Sanchez, Violeta
Rexer, Brent N.
Sanders, Melinda
Zhao, Zhongming
Stricker, Thomas P.
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-302
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
302
引用
收藏
页数：3
相关论文
共 50 条
  • [1] PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer
    Zhang, Hongyan
    Zhang, Longlong
    He, Yuna
    Jiang, Dewei
    Sun, Jian
    Luo, Qianmei
    Liang, Huichun
    Wang, Tiantian
    Li, Fubing
    Tang, Yu
    Yang, Zimo
    Liu, Wenjing
    Rao, Yu
    Chen, Ceshi
    CANCER LETTERS, 2024, 598
  • [2] Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer
    Hanker, Ariella B.
    Estrada, Monica Valeria
    Bianchini, Giampaolo
    Moore, Preston D.
    Zhao, Junfei
    Cheng, Feixiong
    Koch, James P.
    Gianni, Luca
    Tyson, Darren R.
    Sanchez, Violeta
    Rexer, Brent N.
    Sanders, Melinda E.
    Zhao, Zhongming
    Stricker, Thomas P.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2017, 77 (12) : 3280 - 3292
  • [3] Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer (vol 77, pg 3280, 2017)
    Hanker, Ariella B.
    Estrada, Monica Valeria
    Bianchini, Giampaolo
    Moore, Preston D.
    Zhao, Junfei
    Cheng, Feixiong
    Koch, James P.
    Gianni, Luca
    Tyson, Darren R.
    Sanchez, Violeta
    Rexer, Brent N.
    Sanders, Melinda E.
    Zhao, Zhongming
    Stricker, Thomas P.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2019, 79 (04) : 873 - 873
  • [4] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Fujimoto, Yumi
    Morita, Tomoko Yamamori
    Ohashi, Akihiro
    Haeno, Hiroshi
    Hakozaki, Yumi
    Fujii, Masanori
    Kashima, Yukie
    Kobayashi, Susumu S.
    Mukohara, Toru
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [5] Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells
    Yumi Fujimoto
    Tomoko Yamamori Morita
    Akihiro Ohashi
    Hiroshi Haeno
    Yumi Hakozaki
    Masanori Fujii
    Yukie Kashima
    Susumu S. Kobayashi
    Toru Mukohara
    Scientific Reports, 10
  • [6] Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells
    Brent N Rexer
    Siprachanh Chanthaphaychith
    Kimberly Brown Dahlman
    Carlos L Arteaga
    Breast Cancer Research, 16
  • [7] The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer
    Cataldo, Maria Letizia
    De Placido, Pietro
    Esposito, Daniela
    Formisano, Luigi
    Arpino, Grazia
    Giuliano, Mario
    Bianco, Roberto
    De Angelis, Carmine
    Veneziani, Bianca Maria
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [8] PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer
    Parvin F. Peddi
    Sara A. Hurvitz
    Journal of Neuro-Oncology, 2014, 117 : 7 - 13
  • [9] A Mechanistic Logic for Dual Targeting of HER2 and PI3K/AKT/mTOR Signaling in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    Rodrik-Outmezguine, V.
    Scaltriti, M. Maurizio
    Sakr, R.
    Will, M.
    Giri, D.
    Hudis, C.
    Baselga, J.
    King, T.
    Rosen, N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 127 - 127
  • [10] Single agent and combined targeting of PI3K, mTOR, HER2 and ER signaling in a panel of HER2+/ER+ versus HER2+/ER- breast cancer cell lines
    O'Brien, N. A.
    Nichols, C. M.
    Thomas, J.
    Conklin, D.
    Kalous, O.
    Linnartz, R.
    Di Tomasso, E.
    Hurvitz, S. A.
    Hirawat, S.
    Slamon, D. J.
    CANCER RESEARCH, 2016, 76
12345